|
Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis Clinical research trials and Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis. Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis  Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis
Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis
For Condition: Hepatitis C,Vasculitis
Status: Recruiting
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: This study will examine the safety and effectiveness of the drug Rituximab in treating hepatitis C-associated cryoglobulinemic vasculitis. About 5 percent of patients with hepatitis C develop cryoglobulinemic vasculitis. This syndrome, characterized by inflammation of blood vessels (vasculitis), may involve the skin, joints, kidneys, nerves and other sites, and cause skin rashes, joint pain, weakness, fatigue, and numbness. About 10 to 30 percent of patients develop kidney disease, which, in some cases, can lead to kidney failure. Although the cause of cryoglobulinemic vasculitis is not known, a critical component is the presence of cryoglobulins-abnormal proteins that white blood cells called B lymphocytes produce in response to the chronic hepatitis C infection. Rituximab decreases the number of B cells. The Food and Drug Administration approved Rituximab in 1997 for the treatment of B-cell non-Hodgkin's lymphoma. Patients between 18 and 75 years of age with hepatitis C and signs and symptoms of cryoglobulinemic vasculitis may be eligible for this study. They must have failed, or been unable to tolerate, treatment with IFN-a and ribavirin. Candidates will be screened with a history and physical examination, electrocardiogram (ECG), blood and urine tests, 24-hour urine collection and chest X-ray, if clinically indicated. Participants will be randomly assigned to receive Rituximab upon entering the study or 6 months after entering the study. Those whose treatment is delayed 6 months will be followed once a month at NIH for disease evaluation and blood tests during that time. Patients will be given Rituximab intravenously (through a vein) once a week for 4 weeks. For the first dose, patients will be admitted to the hospital for at least 24 hours after the infusion for monitoring. Subsequent infusions will be given on an inpatient or outpatient basis, depending on how the infusion is tolerated. The day before each infusion they will have a history and physical examination, blood work, and other tests, such as X-rays, as clinically indicated. After the four infusions, patients will be followed for drug side effects and response to treatment. They will have blood tests every week for 4 weeks and will then return to NIH for 1 day every month for 12 months for a physical examination, blood tests, and X-rays, if medically indicated. Visits may be more frequent, if necessary, and patients may be asked to stay longer than a day if test findings require further investigation. Patients whose cryoglobulinemic vasculitis improves and remains inactive for 12 months after completing Rituximab therapy will have completed the study. Those who benefit from treatment but have a later worsening of disease may receive a second course of four infusions, with follow-up for 12 months after the last infusion. Patients who do not respond to treatment and whose disease worsens will be advised of other treatment options, but will be asked to return to NIH monthly for 12 months for follow-up.
Details: The purpose of this study is to assess the safety and efficacy of Rituximab (anti-CD20) in the treatment of patients with hepatitis C associated cryoglobulinemic vasculitis (HCV-CV) who have failed or are intolerant to interferon-alpha/ribavirin therapy. Up to 50 patients may be screened to enroll 34 adult patients with active HCV-CV in this randomized, non-blinded phase I/II trial. Patients will be randomized to receive either Rituximab 375 mg/M(2) on days 1, 8, 15 and 22 beginning at the time of enrollment or 6 months following enrollment. Patients in both groups will be maintained on stable doses of any immunosuppressive therapies that they were receiving at the time of enrollment. Response to Rituximab will be assessed by clinical and laboratory parameters.
Eligibility:
Study Type: Interventional, Treatment, Safety/Efficacy
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA Diagnosis of HCV-CV: must have all of the following HCV infection documented by serology and/or plasma HCV RNA. One or more organ system with objective evidence of active vasculitis such as: Palpable purpura; Glomerulonephritis (defined by the presence of glomerular hematuria and/or new or worsening proteinuria); Acute peripheral neuropathy. Detectable cryoglobulins and/or RF. Failure of treatment with IFN-alpha and ribavirin to control manifestations of HCV-CV OR intolerance to IFN-alpha/ribavirin regimen. Patients must have a personal physician responsible for the care of their HCV. Ages of 18 and 75 years Willingness to use effective contraception during and for 12 months following Rituximab treatment. Effective contraception methods include abstinence, surgical sterilization of either partner, barrier methods such as diaphragm, condom, cap or sponge, or hormonal contraception. EXCLUSION CRITERIA Recent (within 4 weeks) initiation of or increase in immunosuppressive therapy. Active systemic infection (other than hepatitis C). Pregnancy or breast feeding. Prior treatment with Rituximab. Known allergy to murine proteins. Significant renal insufficiency (creatinine clearance less than 30 ml/min). Presence of life-threatening HCV-CV; defined as rapidly progressive glomerulonephritis (defined as a doubling of the serum creatinine over a 3 month period), CNS vasculitis, cardiac disease due to active vasculitis, or GI vasculitis (defined by ischemic bowel, perforation, or infarction). Significant hepatic insufficiency as manifested by Child-Pugh classification of B or C. History of variceal bleeding, encephalopathy. History of liver transplantation. Co-infection with either HBV or HIV. Any underlying medical condition that in the judgment of the investigator would put the patient at increased risk for serious infusion-related adverse events.
Total Enrollment: 50
Location and Contact Information:
National Institute of Allergy and Infectious Diseases (NIAID) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting William Sachau 3014357940
Additional Information:
Study ID Numbers: 020096; 02-I-0096
Study Start Date: December 31, 2001
Record last reviewed: December 19, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00029107
Other Hepatitis C Studies:
1. 12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy.
2. Treatment of Cholestatic Pruritus With Sertraline
3. The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon alpha-2b and Ribavirin
4. Treatment of Hepatitis in Patients who are Triple-Infected with HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)
5. Herbal Treatment of Hepatitis C in Methadone Maintained Patients
Related Studies:
Other Hepatitis C Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis
|
|
|
|
|
|
|
|
